SynthesisPloS one2012

Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.

Jiajie Zang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.